|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E </span>mutation in colorectal cancer by immunohistochemistry is a viable alternative to molecular methods.
|
23650027 |
2013 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We provide a global assessment of gene expression motifs that differentiate BRAF V600E subtypes from other colorectal cancers.
|
27354468 |
2017 |
|
rs909797662
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
|
rs909797662
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of <i>KRAS</i> G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
|
31611389 |
2019 |
|
rs909797662
|
|
|
0.040 |
GeneticVariation |
BEFREE |
To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS.
|
27805251 |
2016 |
|
rs909797662
|
|
|
0.040 |
GeneticVariation |
BEFREE |
However, among the various <i>KRAS</i> mutations, that which encodes the G13D mutant protein (KRAS<sup>G13D</sup>) behaves differently; for unknown reasons, KRAS<sup>G13D</sup> CRC patients benefit from the EGFR-blocking antibody cetuximab.
|
31551296 |
2019 |
|
rs2227983
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genotypes with the variant allele of EGFR R521K SNP confer a risk reduction to develop CRC.
|
21896992 |
2011 |
|
rs2227983
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor R497K polymorphism is a favorable prognostic factor for patients with colorectal carcinoma.
|
17575224 |
2007 |
|
rs2227983
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17).
|
30275229 |
2018 |
|
rs1057519860
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our study indicated that EGFR and S492R EGFR accelerate the growth of CRC cells in vitro and in vivo and monoclonal antibody CH12, which specifically recognizes an EGFR tumor-specific epitope, can bind efficiently to S492R EGFR.
|
30671888 |
2019 |
|
rs1057519860
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.
|
24025416 |
2013 |
|
rs1282801317
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the present study, two novel non-hotspot <i>KRAS</i> mutations were functionally characterized <i>in vitro</i>: KRAS E31D was identified from a genetic screen of colorectal cancer specimens at the UP-National Institutes of Health.
|
31289513 |
2019 |
|
rs1383485737
|
|
|
0.010 |
GeneticVariation |
BEFREE |
NTRK gene mutations were identified in MSH2/MLH1-mutant CRC including NTRK1 I699V, NTRK2 P716S, and NTRK3 R745L.
|
28591715 |
2017 |
|
rs397517134
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant association was found between the CCND1 A870G polymorphism and overall survival in our 39 CRC subjects.
|
16788380 |
2006 |
|
rs756703787
|
|
|
0.010 |
GeneticVariation |
BEFREE |
AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
|
25714871 |
2015 |